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Kaposi’s Sarcoma in a Patient with
Erythroblastopenia and Thymoma:
Reactivation after Topical Corticosteroids
Introduction
Kaposi’s sarcoma (KS) is a multicentric
neoplasm with several manifestations, differ-
ent clinical features, evolution and degrees of
malignancy. Clinical forms include classical
KS, endemic KS, epidemic KS and KS in im-
munosuppressed patients. In all of those vari-
ants, HHV-8 has been documented [1].
We report a patient who presented KS
after diagnosis of erythroblastopenia and thy-
moma treated with thymectomy and cortico-
steroids. HHV-8 was observed only in lesional
tissues.
Case Report
A 69-year-old Spanish female came to
our department in July 1993 because of the
appearance of violaceous papules, nodules
and plaques on the legs, trunk, and upper
limbs over the last 5 months.
Medical history revealed that she had
been diagnosed with erythroblastopenia and
thymoma in December 1992. She underwent
thymectomy, and therapy with methylpred-
nisolone 40–80 mg/day was initiated in
January 1993. She required monthly blood
transfusions, and cyclosporine at a dose of
5 mg/kg/day was initiated in July 1993.
Physical examination revealed violace-
ous papules, nodules and plaques on her
lower limbs that were very painful and were
accompanied by edema (fig.1). Other pap-
ules were present on the abdomen, chest,
back and oral mucosa.
The histopathological study from a lesion
of the chest (biopsy No. 1) revealed a vascu-
lar proliferation of mature vessels, together
with a proliferation of spindle cells that were
arranged in fascicles. Red blood cells were
present between the spindle cells (fig.2). The
diagnosis of a KS was established, and radio-
therapy was initiated on the lower limbs with
subsequent resolution of the lesions. In Sep-
tember 1993, corticosteroids and cyclo-
sporine were withdrawn and interferon alfa-
2b, 15 million units per weeks, was initiated,
and residual hyperpigmentation was ob-
served 4 months later.
In January 1994, painful, diffuse oral ul-
cerations appeared. The histopathological
study showed a lichenoid infiltrate (biopsy
No. 2) (fig.3). Two direct immunofluores-
cence tests were negative. A diagnosis of ero-
sive lichen planus was established, and ther-
apy with the topical application of 0.1%
triamcinolone acetonide was begun. One
month later, a violaceous papule appeared on
the dorsum of the tongue. The biopsy con-
firmed the diagnosis of KS (biopsy No. 3)
(fig.4). Topical corticosteroids were stopped,
and no new KS lesions appeared. Differ-
ent therapies were established with topical
anesthetics, nystatine plus fluconazole,
chloroquine, spiramycin and griseofulvin
without response. Topical cyclosporine was
also prescribed, but only a transient im-
provement was obtained. An erythematous
papule appeared inside an ulcerated area,
and the histopathological study only showed
the presence of granulation tissue (biopsy
No. 4).
Laboratory investigation revealed persis-
tent anemia with hemoglobin 50–60 g/l, total
lymphocytes 1,756, with CD4 439 (N
300–3,000), CD8 966 (N 150–2,400), and a
CD4/CD8 ratio 0.45 (N 0.8–2.7). Abnormal
liver function tests, with AST 68 U/l (N
9–25), ALT 149 U/l (N 8–36), alkaline phos-
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Abstract
We report a 69-year-old female with erythroblastopenia and thymoma who developed lesions
of Kaposi’s sarcoma (KS) after thymectomy, 2 months after the initiation of therapy with
methylprednisolone. Control of mucocutaneous KS lesions was obtained with radiotherapy, in-
terferon alfa-2b and withdrawal of systemic immunosuppressive therapy. Erosive oral lichen
planus appeared later, and after therapy with topical corticosteroids a new lesion of KS devel-
oped that regressed after withdrawal of topical corticosteroids. The detection of HHV-8 only in
lesional skin supports the hypothesis that this virus can trigger the development of KS lesions.
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phatase 516 (N 82–198) U/l, g -GTP 172 U/l
(N 7–43). Serological tests for hepatitis C
virus and HIV were negative. Indirect im-
munofluorescence test using guinea pig
esophagus as substrate was negative.
In October 1995, the patient died due to
myocardiopathy secondary to hemosiderosis
as a result of multiple transfusions.
Virological Studies
A PCR amplification for HHV-8 using
DNA isolated from paraffin blocks of the four
biopsies was performed according to the
technique previously published by Simon et
al. [2]. Biopsies of KS from the skin and from
the tongue (No. 1, 3) displayed a PCR amplifi-
cation of approximately 233 bp. Southern
blot hybridization confirmed the results ob-
tained by the UV visualization of the PCR
products in the agarose gel in these cases.
Biopsies of oral lichen planus and granula-
tion tissue (No. 2, 4) were negative (these
studies were performed by C.A.S.).
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Fig. 1. Papules and nodules of KS affecting the lower limbs.
Fig. 2. Histopathological study of biopsy No. 1 shows diffuse proliferation of spindle cells in the reticular dermis
with mature dilated vessels. HE. · 40.
Fig. 3. Histopathological study of biopsy No. 2 from oral ulceration shows a lichenoid dermatitis. HE. · 400.
Fig. 4. Histopathological study of biopsy No. 3 (the papule of the tongue) shows proliferation of spindle cells with
extravasation of red blood cells. HE. · 400.
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Discussion
We think that several factors play a role in
the development of KS in the patient reported
here, such as the presence of thymoma, ery-
throblastopenia, and the previous therapy
with corticosteroids.
KS has been reported in association with a
second neoplasm in 37% of the cases [3].
Lymphoproliferative disorders are the most
frequently observed (60%) [3]. Several cases
of KS associated with thymoma have been re-
ported in the literature [4–13]. The interval
between thymoma diagnosis and KS appear-
ance ranges from a few months to 6 years. As
in our case, some of these patients had been
treated with thymectomy and/or immuno-
suppressive therapy before KS developed
[4–13]. Coexisting KS and thymoma have
been related to myasthenia gravis, immuno-
suppressive therapy, CD4+ lymphopenia
[12] and increase of CD8+ T lymphocyte
counts [11]. This imbalance between CD4+
and CD8+ T lymphocytes has been consid-
ered responsible for the immunosuppression
in patients with thymoma [12].
In our patient, immunosuppressive drugs
may also have played an important role in the
development of KS, as has been described in
patients following corticosteroid therapy for
autoimmune disorders (alone or associated
with other immunosuppressants) [14–19],
solid organ transplantation [20] and other dis-
orders without any underlying neoplastic or
autoimmune disease [14, 19, 21–25]. Ery-
throblastopenia is considered an autoimmune
disorder and is associated with thymoma in
over 50% of the patients. Other autoimmune
disorders have been associated with KS in the
literature [14–19], the most frequent being
pemphigus, rheumatoid arthritis, and autoim-
mune hemolytic anemia.
We suggest that corticosteroids probably
played a more significant role in the de-
velopment of KS than cyclosporine in our
patient because: (1) cyclosporine was initi-
ated 5 months after the development of KS
lesions, and (2) KS developed on the tongue
1 month after the topical application of 0.1%
triamcinolone acetonide for oral lichen
planus, and no new lesions appeared after
withdrawal of this therapy.
It is difficult to prove that interferon alfa-
2b alone was responsible for improvement of
the lesions. Immunosuppressive treatment
was withdrawn in parallel with interferon
alfa-2b initiation, and we have found reports
of spontaneous improvement after immuno-
suppressive therapy was discontinued [14].
In our patient, oral lichen planus appeared
during therapy with interferon alfa-2b. Inter-
feron alfa-2a and -2b have been used to treat
heapatitis caused by the hepatitis C virus.
Both interferon alfa-2a and -2b have been re-
ported to either initiate [26–28] or exacerbate
[29, 30] lichen planus lesions following this
therapy for infection with hepatitis C virus.
On the contrary, other publications describe
clearance [31] or no effect [32] using inter-
feron alfa-2a on oral lichen planus.
Knowledge of HHV-8 has contributed to
the understanding of KS. This virus has been
detected in KS lesions of all types. Sequences
of HHV-8 have also been detected in the un-
involved skin of KS patients in about 35% of
cases and 3% of control S. HHV-8 may be a
widespread latent virus which predisposes to
KS, but cofactors such as immunosuppres-
sion may be required to develop the disease
[1]. The fact that in our patient HHV-8 was
detected in KS lesions of the skin and tongue
but not in lichen planus lesions or granulation
tissue from the oral mucosa supports the hy-
pothesis that this virus plays a role in the de-
velopment of KS lesions.
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